» Articles » PMID: 18021020

Antigen-specific Tolerance of Human Alpha1-antitrypsin Induced by Helper-dependent Adenovirus

Overview
Journal Hum Gene Ther
Specialties Genetics
Pharmacology
Date 2007 Nov 21
PMID 18021020
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

As efficient and less toxic virus-derived gene therapy vectors are developed, a pressing problem is to avoid immune response to the therapeutic gene product. Secreted therapeutic proteins potentially represent a special problem, as they are readily available to professional antigen-presenting cells throughout the body. Some studies suggest that immunity to serum proteins can be avoided in some mouse strains by using tissue-specific promoters. Here we show that expression of human alpha1-antitrypsin (AAT) was nonimmunogenic in the immune-responsive strain C3H/HeJ, when expressed from helper-dependent (HD) vectors using ubiquitous as well as tissue-specific promoters. Coadministration of less immunogenic HD vectors with an immunogenic first-generation vector failed to immunize, suggesting immune suppression rather than immune stealth. Indeed, mice primed with HD vectors were tolerant to immune challenge with hAAT emulsified in complete Freund's adjuvant. Such animals developed high-titer antibodies to coemulsified human serum albumin, showing that tolerance was antigen specific. AAT-specific T cell responses were depressed in tolerized animals, suggesting that tolerance affects both T and B cells. These results are consistent with models of high-dose tolerance of B cells and certain other suppressive mechanisms, and suggest that a high level of expression from HD vectors can be sufficient to induce specific immune tolerance to serum proteins.

Citing Articles

Immunogenicity of Cas9 Protein.

Mehta A, Merkel O J Pharm Sci. 2019; 109(1):62-67.

PMID: 31589876 PMC: 7115921. DOI: 10.1016/j.xphs.2019.10.003.


Challenges and Prospects for Helper-Dependent Adenoviral Vector-Mediated Gene Therapy.

Piccolo P, Brunetti-Pierri N Biomedicines. 2017; 2(2):132-148.

PMID: 28548064 PMC: 5423471. DOI: 10.3390/biomedicines2020132.


Combinatorial treatment with oncolytic adenovirus and helper-dependent adenovirus augments adenoviral cancer gene therapy.

Farzad L, Cerullo V, Yagyu S, Bertin T, Hemminki A, Rooney C Mol Ther Oncolytics. 2016; 1:14008.

PMID: 27119096 PMC: 4782941. DOI: 10.1038/mto.2014.8.


Helper-Dependent Adenoviral Vectors.

Rosewell A, Vetrini F, Ng P J Genet Syndr Gene Ther. 2014; Suppl 5.

PMID: 24533227 PMC: 3923448. DOI: 10.4172/2157-7412.s5-001.


Differential type I interferon-dependent transgene silencing of helper-dependent adenoviral vs. adeno-associated viral vectors in vivo.

Suzuki M, Bertin T, Rogers G, Cela R, Zolotukhin I, Palmer D Mol Ther. 2013; 21(4):796-805.

PMID: 23319058 PMC: 3616533. DOI: 10.1038/mt.2012.277.